Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Research Regulatory News (EDEN)

Share Price Information for Eden Research (EDEN)

Share Price is delayed by 15 minutes
Get Live Data
3.15    0.00 (0.00%)
Bid:
3.10
Ask:
3.20
Spread: 0.10 (3.226%)
Market Cap: £25.31m
EDEN Live PriceLast checked at - London Stock Exchange

Intraday Eden Research Share Chart

AIM Rule 17 Notification

24 Oct 2022 12:00

RNS Number : 8925D
Eden Research plc
24 October 2022
 

24 October 2022

 

Eden Research Plc

("Eden" or the "Company")

AIM Rule 17 Notification

Eden Research Plc (AIM: EDEN) the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces the following additional director disclosure provided pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules.

Richard Horsman, Non-executive director of Eden, is Non-executive chairman of Toople Plc ("Toople"). On 21 October 2022, the Directors of Toople appointed an administrator to preserve value for creditors.

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean SmithAlex Abrey

 

 

01285 359 555

Cenkos Securities plc (Nominated advisor and broker)

Giles Balleny / Max Gould (corporate finance)Michael Johnson (sales)

 

 

020 7397 8900

Hawthorn Advisors (Financial PR)

Victoria AinsworthStephen Atkinson

 

eden@hawthornadvisors.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNUSARRUUURUAA
Date   Source Headline
24th Sep 20137:00 amRNSHalf Yearly Report
28th Aug 20137:00 amRNSNotice of Allowance
27th Aug 201310:33 amRNSHolding(s) in Company
24th Jun 20131:39 pmRNSResult of AGM
24th Jun 20137:00 amRNSAGM Statement
5th Jun 20137:00 amRNSLicence agreement for head lice treatment
31st May 20135:22 pmRNSPosting of Annual Report & Notice of AGM
31st May 20137:08 amRNSPreliminary Results
20th May 20137:00 amRNSEU approval for active substances
25th Apr 20137:00 amRNSNotice of Allowance from ARIPO
16th Apr 201311:40 amRNSHolding(s) in Company
15th Mar 20137:00 amRNSMaster Encapsulation Patent Granted in Europe
15th Feb 20131:59 pmRNSHolding(s) in Company
15th Feb 201310:14 amRNSHolding(s) in Company
15th Feb 201310:00 amRNSHolding(s) in Company
8th Feb 20137:00 amRNSPlacing to raise £1.1m
4th Dec 201212:25 pmRNSDirector/PDMR Shareholding
4th Dec 20127:00 amRNSDirectorate Change
29th Nov 20127:00 amRNSChange of Adviser
27th Nov 20127:00 amRNSAustralian Patent Expansion
9th Nov 20127:00 amRNSNotice of Acceptance of patent in Australia
17th Oct 201210:30 amRNSEU registration milestone reached
27th Sep 20127:00 amRNSHalf Yearly Report
13th Sep 20127:55 amRNSUpdate on Certis Europe
14th Jun 20127:00 amRNSDirector/PDMR Shareholding
12th Jun 201210:43 amRNSResult of AGM
12th Jun 20127:00 amRNSAGM Statement and Business Update
21st May 20124:03 pmRNSPublication of Annual Report and AGM Details
17th May 20121:40 pmRNSHolding(s) in Company
17th May 201211:25 amRNSGrant of Patent
11th May 20128:00 amRNSAIM Admission

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.